JoVE Logo
Faculty Resource Center

Sign In

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

DOI :

10.3791/58651-v

January 7th, 2019

January 7th, 2019

9,139 Views

1Department of Translational Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), 2Faculty of Biosciences, Heidelberg University, 3Department of Medical Oncology, NCT and Heidelberg University Hospital

This protocol describes a detailed workflow for the generation and ex vivo characterization of oncolytic viruses for expression of immunomodulators, using measles viruses encoding bispecific T cell engagers as an example. Application and adaptation to other vector platforms and transgenes will accelerate the development of novel immunovirotherapeutics for clinical translation.

-- Views

Related Videos

article

Transmitochondrial Cybrid Generation Using Cancer Cell Lines

article

Optimization of Performance Parameters of the TAGGG Telomere Length Assay

article

Shear Assay Protocol for the Determination of Single-Cell Material Properties

article

Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment

article

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

article

A Three-Dimensional Technique for the Visualization of Mitochondrial Ultrastructural Changes in Pancreatic Cancer Cells

article

Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures

article

Author Spotlight: Demonstrating Systematic Endobronchial Ultrasound to New Endoscopists

article

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

article

Author Spotlight: Creating Human Vascularized Micro-Tumors as Models for Translational Cancer Research

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved